Cambridge Investment Research Advisors, Inc. Immuno Gen, Inc. Transaction History

Cambridge Investment Research Advisors, Inc.

$29.4 Billion
Q3 2024

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 24, 2023	SELL	$14.09 - $19.87 $29,180 - $41,150	-2,071 Reduced 8.84%	21,362 $339,000
Q2 2023 Jul 13, 2023	SELL	$3.75 - $20.05 $104,880 - $560,758	-27,968 Reduced 54.41%	23,433 $442,000
Q1 2023 May 11, 2023	BUY	$3.67 - $4.92 $2,334 - $3,129	636 Added 1.25%	51,401 $197,000
Q4 2022 Feb 08, 2023	SELL	$4.55 - $6.31 $12,275 - $17,024	-2,698 Reduced 5.05%	50,765 $252,000
Q3 2022 Oct 17, 2022	SELL	$4.48 - $6.47 $448 - $647	-100 Reduced 0.19%	53,463 $255,000
Q2 2022 Jul 13, 2022	BUY	$3.15 - $5.76 $80,605 - $147,392	25,589 Added 91.47%	53,563 $241,000
Q1 2022 May 12, 2022	BUY	$4.26 - $7.48 $421 - $740	99 Added 0.36%	27,974 $133,000
Q4 2021 Feb 03, 2022	BUY	$4.75 - $7.5 $43,643 - $68,910	9,188 Added 49.17%	27,875 $206,000
Q3 2021 Nov 02, 2021	BUY	$5.02 - $6.59 $93,808 - $123,147	18,687 New	18,687 $105,000
Q1 2021 May 07, 2021	SELL	$6.5 - $10.53 $112,924 - $182,937	-17,373 Closed	0 $0
Q4 2020 Feb 04, 2021	SELL	$3.7 - $7.66 $9,224 - $19,096	-2,493 Reduced 12.55%	17,373 $112,000
Q3 2020 Oct 29, 2020	BUY	$3.45 - $4.89 $345 - $488	100 Added 0.51%	19,866 $71,000
Q1 2020 May 08, 2020	BUY	$2.12 - $6.8 $6,979 - $22,385	3,292 Added 19.98%	19,766 $67,000
Q3 2019 Oct 28, 2019	BUY	$2.22 - $3.39 $36,572 - $55,846	16,474 New	16,474 $39,000

Others Institutions Holding IMGN

# of Institutions

Shares Held

1.41M

Call Options Held

Put Options Held

View Full List

About ImmunoGen, Inc.

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

More about IMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cambridge Investment Research Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cambridge Investment Research Advisors, Inc. with notifications on news.

Account